Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Xenon (XENE)
NASDAQ:XENE
Holding XENE?
Track your performance easily
Earnings Data
Report Date
Feb 26, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.86Last Year’s EPS
-0.64Same Quarter Last Year
Strong Buy
Based on 11 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 06, 2018
|% Change Since: -11.22%
|Next Earnings Date:Aug 07, 2018
Earnings Call Sentiment|Positive
The overall sentiment of the earnings call is positive, with significant progress in clinical programs, strong financial health, and anticipation of important milestones in 2025. However, there are concerns about decreased cash reserves and potential enrollment challenges.Company Guidance
In the third quarter 2024 earnings call for Xenon Pharmaceuticals, the company provided guidance on multiple fronts, including the projected timelines and strategic plans for their leading product, azetukalner. The company anticipates having sufficient cash reserves to fund operations into 2027, demonstrating a strong financial position with cash and equivalents of $803.3 million as of September 30, 2024. Xenon emphasized the promising clinical data of azetukalner in epilepsy, highlighting over 600 patient years of exposure and a substantial reduction in seizure frequency, with some patients achieving long-term seizure freedom. The company is gearing up for a significant presence at the American Epilepsy Society Meeting in December 2024, where they plan to present updated 36-month data from their X-TOLE open-label extension study. Moreover, Xenon's ongoing Phase III programs in epilepsy and major depressive disorder (MDD) are tracking as planned, with the first top-line readouts expected in the second half of 2025 for the X-TOLE2 study. The company is also advancing its early-stage pipeline with multiple Kv7 and Nav1.7 candidates, aiming to file INDs or equivalents in 2025, thus reinforcing their leadership in ion channel therapeutics development.Progress in Azetukalner Development
Xenon Pharmaceuticals has made significant progress in the development of azetukalner, a highly potent and selective Kv7 potassium channel opener, for use in epilepsy and major depressive disorder (MDD). The company is advancing its Phase III epilepsy and MDD programs and expects to initiate the X-NOVA2 trial before the end of the year.
Strong Financial Position
As of September 30, 2024, Xenon reported having $803.3 million in cash and cash equivalents, which is expected to fund operations into 2027, supporting the completion of Phase III studies for azetukalner and other development activities.
Anticipated Key Milestones in 2025
Xenon anticipates pivotal milestones in 2025, including top-line data from the X-TOLE2 epilepsy study in the second half of the year and results from a Phase II MDD study in the first half of the year.
Expansion of Clinical Pipeline
The company is advancing its early-stage pipeline, with plans to file multiple INDs in 2025, including for new Kv7 candidates and Nav1.7 sodium channel inhibitors.
---
XENE Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
XENE Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $43.39 | $41.97 | -3.27% |
| Aug 08, 2024 | $41.01 | $39.70 | -3.19% |
| May 09, 2024 | $42.49 | $40.54 | -4.59% |
| Feb 29, 2024 | $47.20 | $46.84 | -0.76% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Xenon (XENE) report earnings?
Xenon (XENE) is schdueled to report earning on Feb 26, 2025, TBA Not Confirmed.
What is Xenon (XENE) earnings time?
Xenon (XENE) earnings time is at Feb 26, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is XENE EPS forecast?
XENE EPS forecast for the fiscal quarter 2024 (Q4) is -0.86.
---